Crossmark Global Holdings’s Enanta Pharmaceuticals ENTA Stock Holding History

Crossmark Global Holdings’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,540	Closed	-$219K	–	1304
2019 Q4	$219K	Buy	+3,540	New	+$219K	0.01%	1297
2018 Q4	–	Sell	-7,950	Closed	-$679K	–	1440
2018 Q3	$679K	Sell	7,950 -150	-2%	-$15K	0.02%	773
2018 Q2	$939K	Buy	8,100 +420	+5%	+$41.9K	0.03%	620
2018 Q1	$621K	Sell	7,680 -620	-7%	-$47.7K	0.02%	797
2017 Q4	$487K	Buy	8,300 +2,130	+35%	+$107K	0.01%	1023
2017 Q3	$289K	Buy	+6,170	New	+$248K	0.01%	1341
2016 Q3	$289K	Buy	+6,170	New	+$143K	0.01%	1341

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Crossmark Global Holdings's ENTA Position: Q1 2020 in Review

Crossmark Global Holdings sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 3,540 shares — an estimated $219K sold.

Crossmark Global Holdings first reported a position in ENTA in Q3 2016 and held it in 7 quarters. The position peaked at $939K in Q2 2018. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

Crossmark Global Holdings reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Crossmark Global Holdings sold 3,540 Enanta Pharmaceuticals shares in Q1 2020, an estimated $219K.
Crossmark Global Holdings first reported a position in Enanta Pharmaceuticals in Q3 2016 and held it in 7 quarters.
Crossmark Global Holdings's Enanta Pharmaceuticals position peaked at $939K in Q2 2018.
156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Crossmark Global Holdings's 13F filing for Q1 2020, filed 28 Apr 2020.